ASX - By Stock
|
PAA |
Re:
Ann: FDA Outlines Pathway to Accelerated Approval for MPL in MND
|
|
kpax
|
58 |
16K |
26 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
58
|
16K
|
26
|
|
ASX - By Stock
|
PAA |
Best ASX stock Pharmaust for the next 10 years
|
|
kpax
|
9 |
2.8K |
33 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
9
|
2.8K
|
33
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Extension Study Begins, Analysis Suggests Survival Benefit
|
|
kpax
|
197 |
54K |
37 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
197
|
54K
|
37
|
|
ASX - By Stock
|
PAA |
Re:
MY INPUT REGARDING PAA AND SARS-COV-2.
|
|
kpax
|
41 |
9.4K |
12 |
06/02/24 |
06/02/24 |
ASX - By Stock
|
41
|
9.4K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
kpax
|
323 |
78K |
20 |
05/02/24 |
05/02/24 |
ASX - By Stock
|
323
|
78K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
kpax
|
323 |
78K |
12 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
323
|
78K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
kpax
|
323 |
78K |
12 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
323
|
78K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
kpax
|
323 |
78K |
29 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
323
|
78K
|
29
|
|
ASX - By Stock
|
PAA |
Re:
Sparks Valuation Pharmaust
|
|
kpax
|
111 |
35K |
29 |
28/01/24 |
28/01/24 |
ASX - By Stock
|
111
|
35K
|
29
|
|
ASX - By Stock
|
PAA |
Re:
Sparks Valuation Pharmaust
|
|
kpax
|
111 |
35K |
13 |
20/01/24 |
20/01/24 |
ASX - By Stock
|
111
|
35K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Sparks Valuation Pharmaust
|
|
kpax
|
111 |
35K |
16 |
20/01/24 |
20/01/24 |
ASX - By Stock
|
111
|
35K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Sparks Valuation Pharmaust
|
|
kpax
|
111 |
35K |
24 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
111
|
35K
|
24
|
|
ASX - By Stock
|
PAA |
Sparks Valuation Pharmaust
|
|
kpax
|
111 |
35K |
37 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
111
|
35K
|
37
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
kpax
|
430 |
111K |
20 |
17/01/24 |
17/01/24 |
ASX - By Stock
|
430
|
111K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAAOA Top 20 & Distribution Report
|
|
kpax
|
43 |
11K |
3 |
14/01/24 |
14/01/24 |
ASX - By Stock
|
43
|
11K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAAOA Top 20 & Distribution Report
|
|
kpax
|
43 |
11K |
4 |
14/01/24 |
14/01/24 |
ASX - By Stock
|
43
|
11K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAAOA Top 20 & Distribution Report
|
|
kpax
|
43 |
11K |
4 |
14/01/24 |
14/01/24 |
ASX - By Stock
|
43
|
11K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Alzheimer's and Monepantel
|
|
kpax
|
18 |
4.8K |
12 |
05/01/24 |
05/01/24 |
ASX - By Stock
|
18
|
4.8K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Alzheimer's and Monepantel
|
|
kpax
|
18 |
4.8K |
30 |
04/01/24 |
04/01/24 |
ASX - By Stock
|
18
|
4.8K
|
30
|
|
ASX - By Stock
|
PAA |
Alzheimer's and Monepantel
|
|
kpax
|
18 |
4.8K |
43 |
04/01/24 |
04/01/24 |
ASX - By Stock
|
18
|
4.8K
|
43
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
kpax
|
430 |
111K |
24 |
01/01/24 |
01/01/24 |
ASX - By Stock
|
430
|
111K
|
24
|
|
ASX - By Stock
|
PAA |
Pharmaust brand name required
|
|
kpax
|
30 |
6.3K |
20 |
28/12/23 |
28/12/23 |
ASX - By Stock
|
30
|
6.3K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
kpax
|
430 |
111K |
28 |
15/12/23 |
15/12/23 |
ASX - By Stock
|
430
|
111K
|
28
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
kpax
|
430 |
111K |
9 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
430
|
111K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
kpax
|
430 |
111K |
8 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
430
|
111K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
kpax
|
430 |
111K |
13 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
430
|
111K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
kpax
|
430 |
111K |
14 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
430
|
111K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
kpax
|
430 |
111K |
16 |
02/12/23 |
02/12/23 |
ASX - By Stock
|
430
|
111K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
kpax
|
430 |
111K |
20 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
430
|
111K
|
20
|
|
ASX - By Stock
|
PAA Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
kpax
|
355 |
70K |
22 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
355
|
70K
|
22
|
|
ASX - By Stock
|
PAA |
Life extension possibilities Monepantel
|
|
kpax
|
3 |
1.2K |
29 |
24/11/23 |
24/11/23 |
ASX - By Stock
|
3
|
1.2K
|
29
|
|
ASX - By Stock
|
PAA Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
kpax
|
355 |
70K |
17 |
23/11/23 |
23/11/23 |
ASX - By Stock
|
355
|
70K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Results of Annual General Meeting
|
|
kpax
|
29 |
7.5K |
30 |
21/11/23 |
21/11/23 |
ASX - By Stock
|
29
|
7.5K
|
30
|
|
ASX - By Stock
|
PAA |
Trial Centre Monepantel Pharmaust
|
|
kpax
|
8 |
1.9K |
32 |
16/11/23 |
16/11/23 |
ASX - By Stock
|
8
|
1.9K
|
32
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Full takeover versus multiple deals?
|
|
kpax
|
76 |
13K |
15 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
76
|
13K
|
15
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Full takeover versus multiple deals?
|
|
kpax
|
76 |
13K |
1 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
76
|
13K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Full takeover versus multiple deals?
|
|
kpax
|
76 |
13K |
6 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
76
|
13K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Full takeover versus multiple deals?
|
|
kpax
|
76 |
13K |
22 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
76
|
13K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
kpax
|
83 |
16K |
22 |
31/10/23 |
31/10/23 |
ASX - By Stock
|
83
|
16K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
kpax
|
83 |
16K |
11 |
31/10/23 |
31/10/23 |
ASX - By Stock
|
83
|
16K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
kpax
|
83 |
16K |
30 |
30/10/23 |
30/10/23 |
ASX - By Stock
|
83
|
16K
|
30
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
kpax
|
45 |
13K |
11 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
45
|
13K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
kpax
|
380 |
85K |
16 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
380
|
85K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
kpax
|
380 |
85K |
34 |
01/10/23 |
01/10/23 |
ASX - By Stock
|
380
|
85K
|
34
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Notification of expiry of quoted options
|
|
kpax
|
43 |
9.5K |
15 |
29/09/23 |
29/09/23 |
ASX - By Stock
|
43
|
9.5K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
$1 party
|
|
kpax
|
21 |
4.8K |
5 |
29/09/23 |
29/09/23 |
ASX - By Stock
|
21
|
4.8K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
$1 party
|
|
kpax
|
21 |
4.8K |
3 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
21
|
4.8K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
kpax
|
380 |
85K |
29 |
20/09/23 |
20/09/23 |
ASX - By Stock
|
380
|
85K
|
29
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
kpax
|
380 |
85K |
12 |
14/09/23 |
14/09/23 |
ASX - By Stock
|
380
|
85K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Chief Executive Officer Appointment
|
|
kpax
|
95 |
23K |
15 |
04/09/23 |
04/09/23 |
ASX - By Stock
|
95
|
23K
|
15
|
|